J&J to send 2 million COVID-19 vaccines – President Ramaphosa

by Editor
0 comments
South Africa's President Cyril Ramaphosa arrives at the Grand Palais Ephemere for the Financing of African Economies Summit, at the Champs de Mars in Paris, France May 18, 2021. Ian Langsdon/Pool via REUTERS

JOHANNESBURG- President Cyril Ramaphosa said on Tuesday that Johnson & Johnson ( J&J )  would send 2 million COVID-19 vaccine doses to the country by the end of the month, making up for the amount lost due to contamination at an U.S. ingredient supplier.

Aspen Pharmacare , J&J’s local producer, had to destroy 2 million doses of the vaccine after the contamination at a plant in Baltimore, Maryland, was discovered, the latest blow to South Africa’s struggling vaccination campaign. 

A box of Johnson & Johnson's coronavirus disease (COVID-19) vaccines is seen at the Forem vaccination centre in Pamplona, Spain, April 22, 2021. REUTERS/Vincent West
A box of Johnson & Johnson’s coronavirus disease (COVID-19) vaccines is seen at the Forem vaccination centre in Pamplona, Spain, April 22, 2021. REUTERS/Vincent West

“We have received an indication from Johnson & Johnson that it expects to deliver around 2 million vaccines to South Africa by the end of the month,” Ramaphosa said in a televised address.

He also announced that the country, which is in the grip of a third wave of infections, would move from an adjusted lockdown level 2 to the stricter level 3 amid a surge in infections. This will include restrictions on alcohol sales and tougher rules around gatherings.

Ramaphosa said now that vaccine supply issues had been resolved, the country had the estimated capacity to vaccinate at least 150,000 people per day and was planning to increase that to 250,000 as soon as possible.

“I would prefer 300,000 per day, which we will try and reach,” he said.Reporting by Emma Rumney Editing by Chris Reese @REUTERS


DO YOU HAVE A NEWS STORY OR AN OPINION FOR CENTRAL NEWS: E-mail us : newsroom@centralnews.co.za or Whatsapp us on 083 398 9119

Related Articles

Leave a Comment

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept